Zurich Cantonal Bank
CRSP icon

Zurich Cantonal Bank’s CRISPR Therapeutics CRSP Stock Holding History

Zurich Cantonal Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,039
Closed -$1.68M – 2808
2025
Q4 		$1.68M Buy
+32,039
New +$1.92M ﹤0.01% 1046

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Zurich Cantonal Bank's CRSP Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 86,029 shares worth $4.09M. The stake represents 0.01% of the portfolio and ranks #723 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in CRSP as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in CRSP in Q3 2017 and has held it in 34 quarters since. The position peaked at $7.36M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Zurich Cantonal Bank held 86,029 shares of CRISPR Therapeutics worth $4.09M as of Q1 2026.
  • CRISPR Therapeutics was a new Zurich Cantonal Bank position in Q1 2026.
  • CRISPR Therapeutics made up 0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #723 holding.
  • Zurich Cantonal Bank first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 34 quarters since.
  • Zurich Cantonal Bank's CRISPR Therapeutics position peaked at $7.36M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.